NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD
INMODE LTD
NASDAQ:INMD (2/5/2025, 10:50:09 AM)
18.065
+0.57 (+3.23%)
The current stock price of INMD is 18.065 USD. In the past month the price increased by 2.88%. In the past year, price decreased by -32.59%.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial...
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its...
/PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.13 | 227.85B | ||
ISRG | INTUITIVE SURGICAL INC | 80.14 | 209.22B | ||
BSX | BOSTON SCIENTIFIC CORP | 44.85 | 156.00B | ||
SYK | STRYKER CORP | 32.53 | 151.16B | ||
MDT | MEDTRONIC PLC | 17.39 | 117.10B | ||
BDX | BECTON DICKINSON AND CO | 18.54 | 70.75B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.97 | 42.47B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.6 | 39.71B | ||
IDXX | IDEXX LABORATORIES INC | 41.27 | 38.01B | ||
RMD | RESMED INC | 27.58 | 35.79B | ||
DXCM | DEXCOM INC | 51.71 | 34.34B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.5 | 25.62B |
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 581
Company Website: https://inmodemd.com/
Investor Relations: https://inmodemd.com/investors/
Phone: 97249097470
The current stock price of INMD is 18.065 USD.
The exchange symbol of INMODE LTD is INMD and it is listed on the Nasdaq exchange.
INMD stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for INMD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of INMD.
INMD does not pay a dividend.
The PE ratio for INMD is 10.15. This is based on the reported non-GAAP earnings per share of 1.78 and the current share price of 18.065 USD.
The outstanding short interest for INMD is 8.39% of its float.
ChartMill assigns a technical rating of 2 / 10 to INMD. When comparing the yearly performance of all stocks, INMD is a bad performer in the overall market: 86.78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to INMD. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.78. The EPS increased by -30.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 36.26% | ||
ROA | 18.65% | ||
ROE | 20.85% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to INMD. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 15.77% and a revenue growth -0.75% for INMD